TAS-102 Combined With Bevacizumab for Second-line Maintenance Treatment of Advanced Colorectal Cancer

NCT06293014 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

224

Enrollment

OTHER_GOV

Sponsor class

Conditions

Colorectal Cancer

Interventions

DRUG: TAS-102+bevacizumab
DRUG: Standard chemotherapy+bevacizumab

Sponsor

Henan Cancer Hospital